Arovella Therapeutics Limited · ASX:ALA

Arovella Therapeutics — Investor Presentation (January 2023)

26 slides from Arovella Therapeutics's investor presentation, Jan 19, 2023

Slide 1: Investor Presentation January 2023
For personal use only ASX:ALA Investor Presentation January 2023
Slide 2: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). For pers
Slide 3: Arovella Therapeutics Highlights
Arovella Therapeutics Highlights For personal use only Allogeneic iNKT Cell Platform World Leading Partners Strong Leadership Group Arovella is developing off-the-shelf iNKT cell Arovella’s technologies are licensed from Arovella’s leadership team and its Board therapies for CD19 expressing lymphoma
Slide 4: Cell Therapy Has Revolutionized Blood Cancer Treatment
Cell Therapy Has Revolutionized Blood Cancer Treatment  CAR-T cells have demonstrated ability to cure haematological cancers For personal use only BUT…….  Manufacturing, logistics and access have prevented broader patient uptake  Arovella’s CAR-iNKT cell platform addresses these challenges and ha
Slide 5: iNKT Cells are Primed to Kill Cancer
iNKT Cells are Primed to Kill Cancer  invariant Natural Killer T (iNKT) cells naturally target and kill cancer For personal use only cells1  The invariant T Cell Receptor (TCR) does not change between people and iNKT cells are protective against graft versus host disease (GVHD) 2,3  Can be admini
Slide 6: CAR-iNKT Cell Therapy is a Superior Cell Therapy Platform
CAR-iNKT Cell Therapy is a Superior Cell Therapy Platform For personal use only iNKT cells are a subpopulation of T cells that have NK cells properties APPROVED ALLOGENEIC ALLOGENEIC CAR-iNKT CAR-T CELLS CAR-T CELLS CAR-NK CELLS CELLS Multiple Cancer Targeting Mechanisms (iTCR- CD1d mediated)   
Slide 7: CAR-iNKT Cell Therapy Production Advantages
CAR-iNKT Cell Therapy Production Advantages Manufacturing For personal use only Collect Healthy Isolate iNKT cells Reprogram iNKT cells to Expand to grow billions of Vial and freeze Donor Blood produce a CAR CAR-iNKT cells CAR-iNKT cells Dosing Thaw CAR-iNKT cells Allogeneic Manufacturing Advantages
Slide 8: Arovella Therapeutics Cell Therapy Pipeline
Arovella Therapeutics Cell Therapy Pipeline For personal use only Cell Therapy Partner Discovery Lead Optimisation IND-Enabling Phase 1 CAR19-iNKT CD19 Expressing Lymphoma (ALA-101) ALA-101 + Solid Tumors onCARlytics Multiple Myeloma TNBC DKK1-CAR-iNKT (ALA-104) NSCLC Pancreatic TNBC – triple negati
Slide 10: ALA-101: Enhanced Tumor Killing In Vivo
ALA-101: Enhanced Tumor Killing In Vivo For personal use only ALA-101 rapidly eradicates tumor cells PBS T iNKT CAR19-T ALA-101 in mice  Tumor cells expressing CD19 and CD1d were intravenously delivered into mice Ventral  Mice were treated with: Day 0  PBS (saline) Dorsal  Unmodified T cells (T)
Slide 11: ALA-101: Superior Animal Survival Over CAR-T Cells
ALA-101: Superior Animal Survival Over CAR-T Cells For personal use only ALA-101 significantly increased survival in mice versus treatment with CAR19-T cells  Tumor cells expressing CD19 and CD1d were intravenously delivered into mice  Mice were treated with:  PBS (saline)  Unmodified T cells (T
Slide 12: ALA-101: Spontaneous Secondary Remission
ALA-101: Spontaneous Secondary Remission For personal use only ALA-101 activity may persist to eradicate tumor cells following relapse Ventral  Four mice treated with ALA-101 had the cancer return to the brain  In all four mice, the cancer was eliminated a second time with no Dorsal additional dos
Slide 13: ALA-101 + CF33-CD19
For personal use only ALA-101 + CF33-CD19 An off-the-shelf cell therapy and oncolytic virus combination to mark and destroy solid tumors © Copyright Arovella Therapeutics Ltd 2023
Slide 14: Combining ALA-101 and CF33-CD19 (onCARlytics)
Combining ALA-101 and CF33-CD19 (onCARlytics) For personal use only  ALA-101 is very potent and is rapidly  CF33 is an oncolytic virus that targets tumor activated to kill CD19 expressing cancers1 cells and not healthy cells2  The product is being developed as an off-  CF33 has been further engi
Slide 16: Expanding ALA-101's Utility by Combining with onCARlytics
Expanding ALA-101’s Utility by Combining with onCARlytics For personal use only  We expect ALA-101 to be effective against blood cancers that naturally express CD19  Combining onCARlytics with ALA-101 cells opens up the possibility of treating a range of solid tumors 16 © Copyright Arovella Therap
Slide 17: DKK1-CAR-iNKT Cells (ALA-104)
For personal use only DKK1-CAR-iNKT Cells (ALA-104) An off-the-shelf cell therapy for multiple myeloma and potentially solid tumors © Copyright Arovella Therapeutics Ltd 2023
Slide 18: DKK1 is a Novel Cancer Target
DKK1 is a Novel Cancer Target  DKK1 is a secreted protein that functions as a For personal use only negative regulator of the WNT signaling pathway1  DKK1 is overexpressed in numerous cancer types and DKK1 peptides are loaded onto immune complexes and presented at the surface of cancer cells2,3,4,
Slide 19: The DKK1 CAR has been Validated in CAR-T Cells
The DKK1 CAR has been Validated in CAR-T Cells  Demonstrated activity of the DKK1 For personal use only Already Completed In Progress peptide-targeting mAb against multiple myeloma and breast cancer  DKK1-CAR-T cells show potent activity against both blood cancers and solid tumors (unpublished) 
Slide 20: DKK1-CAR-T Cell Activity Against Multiple Myeloma
DKK1-CAR-T Cell Activity Against Multiple Myeloma DKK1-CAR-T cells were tested in three different animal models of multiple myeloma, displaying robust activity in all For personal use only standard models Model 1 – U266 (n=4) Model 2 – KMS-12-BM (n=4) Model 3 – MM.1S (n=4) 100 100 100 S u r v iv a l
Slide 21: DKK1-CAR-T Preclinical Safety
DKK1-CAR-T Preclinical Safety Data demonstrates: For personal use only  They only kill cells that have the target on their surface  They do not kill healthy blood cells  They do not cause weight loss when administered to mice  The DKK1 mAb non-specifically targeted only 1 out of 35 tissues teste
Slide 22: Arovella's Potential Cancer Targets
Arovella’s Potential Cancer Targets For personal use only ALA-101 ALA-101 + onCARlytics ALA-104 Non-Hodgkin’s Head and Neck Prostate Cancer Brain Triple Negative Pancreatic Lung Cancer Multiple Lymphoma Cancer Metastases Breast Cancer Cancer Myeloma 22 © Copyright Arovella Therapeutics Ltd 2023
Slide 23: Arovella's Key Milestones Over Months
Arovella’s Key Milestones Over 18 Months Cell Therapy For personal use only Partner Discovery Lead Optimisation IND-Enabling Phase 1 CAR19-iNKT CD19 Expressing Lymphoma (ALA-101) ALA-101 + Solid Tumors onCARlytics Multiple Myeloma TNBC DKK1-CAR-iNKT (ALA-104) NSCLC Pancreatic TNBC – triple negative
Slide 24: Arovella Has a Strong Leadership Team
Arovella Has a Strong Leadership Team LEADERSHIP For personal use only Dr. Michael Baker Dr. Nicole van der Weerden Dr. Mini Bharathan Dr. Sandhya Buchanan Ana Radeljevic CEO & MANAGING DIRECTOR CHIEF OPERATING OFFICER SENIOR VP DEVELOPMENT & MANUFACTURING & QUALITY BUSINESS DEVELOPMENT TRANSLATIONA
Slide 25: Summary – Arovella's CAR-iNKT Cell Platform
Summary – Arovella’s CAR-iNKT Cell Platform A novel allogeneic CAR-iNKT cell platform Arovella has an expanding pipeline For personal use only iNKT cells serve as an excellent platform to ALA-101 and ALA-104 both have the potential to be develop allogeneic cell therapies to treat used to treat haema

Arovella Therapeutics — Investor Presentation (January 2023) on 6ix

Arovella Therapeutics — Investor Presentation (January 2023)

Slide 1: Investor Presentation January 2023

Slide 2: Disclaimer

Slide 3: Arovella Therapeutics Highlights

Slide 4: Cell Therapy Has Revolutionized Blood Cancer Treatment

Slide 5: iNKT Cells are Primed to Kill Cancer

Slide 6: CAR-iNKT Cell Therapy is a Superior Cell Therapy Platform

Slide 7: CAR-iNKT Cell Therapy Production Advantages

Slide 8: Arovella Therapeutics Cell Therapy Pipeline

Slide 9: CAR19-iNKT (ALA-101)

Slide 10: ALA-101: Enhanced Tumor Killing In Vivo

Slide 11: ALA-101: Superior Animal Survival Over CAR-T Cells

Slide 12: ALA-101: Spontaneous Secondary Remission

Slide 13: ALA-101 + CF33-CD19

Slide 14: Combining ALA-101 and CF33-CD19 (onCARlytics)

Slide 15: ALA-101 + onCARlytics Mechanism of Action

Slide 16: Expanding ALA-101's Utility by Combining with onCARlytics

Slide 17: DKK1-CAR-iNKT Cells (ALA-104)

Slide 18: DKK1 is a Novel Cancer Target

Slide 19: The DKK1 CAR has been Validated in CAR-T Cells

Slide 20: DKK1-CAR-T Cell Activity Against Multiple Myeloma

Slide 21: DKK1-CAR-T Preclinical Safety

Slide 22: Arovella's Potential Cancer Targets

Slide 23: Arovella's Key Milestones Over Months

Slide 24: Arovella Has a Strong Leadership Team

Slide 25: Summary – Arovella's CAR-iNKT Cell Platform

Slide 26: Thank You